This company listing is no longer active
Mithra Pharmaceuticals Valuation
Is 1TM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1TM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1TM (€0.18) is trading below our estimate of fair value (€21.02)
Significantly Below Fair Value: 1TM is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1TM?
Key metric: As 1TM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 1TM's PS Ratio? | |
|---|---|
| PS Ratio | 0.4x |
| Sales | €40.16m |
| Market Cap | €14.93m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.8x |
| Enterprise Value/EBITDA | -5.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 1TM's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.5x | ||
B8FK Biofrontera | 0.8x | n/a | €15.8m |
93M1 MPH Health Care | 0.9x | -60.2% | €102.8m |
SBX SynBiotic | 7.2x | 39.7% | €27.9m |
0RX Redx Pharma | 13.3x | -37.6% | €65.0m |
1TM Mithra Pharmaceuticals | 0.4x | 43.1% | €14.9m |
Price-To-Sales vs Peers: 1TM is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (4.6x).
Price to Sales Ratio vs Industry
How does 1TM's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: 1TM is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Pharmaceuticals industry average (3.8x).
Price to Sales Ratio vs Fair Ratio
What is 1TM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | 4.7x |
Price-To-Sales vs Fair Ratio: 1TM is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.55
7D
2.0%
1Y
95.6%
Collegium Pharmaceutical
US$993.0m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.20
7D
5.0%
1Y
23.7%
Pharming Group
€478.2m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.72
7D
1.8%
1Y
-31.2%